Gilead Sciences Inc. (NASDAQ:GILD) has moved back into the U.S. investment-grade debt market, launching a bond sale roughly 18 months after its previous issuance. The company is offering notes in as many as four tranches, with stated maturities that span two to eight years.
Initial price talk for the longest-dated piece of the deal was reported at a yield approximately 0.8 percentage point above Treasuries. Gilead has indicated that the money raised will be used for general corporate purposes - language that can include financing acquisitions or other investments.
The debt offering follows a period of active dealmaking by the drug developer. Gilead announced last week it expects to book $11.5 billion of charges this year tied to recent takeover agreements. Among those transactions is the agreement reached last month to acquire German biotech Tubulis GmbH, a deal Gilead said it planned to partially fund with senior unsecured notes.
Gilead's most recent appearance in the high-grade bond market occurred in November 2024, when it sold $3.5 billion of debt. The current sale is being managed by Barclays Plc (LON:BARC), Bank of America Corp. (NYSE:BAC) and Citigroup Inc. (NYSE:C).
Context and market implications
By re-entering the investment-grade market, Gilead is tapping debt funding as it integrates multiple acquisition commitments and recognizes related charges. The reported pricing talk for the longer maturity provides a snapshot of investor demand and relative risk pricing versus government debt, while the stated use of proceeds preserves flexibility for the company to allocate capital across corporate needs.
Transaction logistics
The structure described - up to four tranches maturing between two and eight years - suggests Gilead is targeting a range of investors across the short- and intermediate-term ends of the investment-grade curve. Barclays, Bank of America and Citigroup are acting as arrangers on the sale.
Takeaways
- Gilead has launched a multi-part investment-grade bond offering after an 18-month absence from the market.
- Proceeds are directed to general corporate purposes, which may include financing recent acquisitions and investments.
- The company expects $11.5 billion of charges this year related to recent takeover agreements, including the Tubulis GmbH deal.